Does aspirin attenuate the beneficial effect of ACE inhibitors in elderly people with heart failure?

Drugs and Aging

Volumn 22, Issue 7, 2005, Pages 605-614

  Pedone, Claudio ^a   Cecchi, Enrica ^b   Matucci, Rosanna ^b   Pahor, Marco ^c   Carosella, Luciana ^d   Bernabei, Roberto ^d   Mugelli, Alessandro ^b  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c WAKE FOREST UNIVERSITY   (United States)

^d CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; LISINOPRIL; LOSARTAN; RAMIPRIL;

AGE DISTRIBUTION; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HAZARD ASSESSMENT; HEART FAILURE; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ASPIRIN; CYCLOOXYGENASE INHIBITORS; DRUG INTERACTIONS; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HUMANS; MALE; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE;

EID: 24044492873     PISSN: 1170229X     EISSN: 1170229X     Source Type: Journal    
DOI: 10.2165/00002512-200522070-00006     Document Type: Article

References (54)

1. Pitt B. Use of converting enzyme inhibitors in patients with asymptomatic left ventricular dysfunction. J Am Coll Cardiol 1993; 22 (4 Suppl. A): 158A-61A
2. Al Khadra AS, Salem DN, Rand WM, et al. Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. J Am Coll Cardiol 1998; 31 (2): 419-25
3. Cleland JG, Bulpitt CJ, Falk RH, et al. Is aspirin safe for patients with heart failure? Br Heart J 1995; 74 (3): 215-9
4. Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). Am J Cardiol 1997; 79 (2): 115-9
5. Feenstra J, Grobbee DE, Mosterd A, et al. Adverse cardiovascular effects of NSAIDs in patients with congestive heart failure. Drug Saf 1997; 17 (3): 166-80
6. Guazzi MD, Campodonico J, Celeste F, et al. Antihypertensive efficacy of angiotensin converting enzyme inhibition and aspirin counteraction. Clin Pharmacol Ther 1998; 63 (1): 79-86
7. Townend JN, Doran J, Lote CJ, et al. Peripheral haemodynamic effects of inhibition of prostaglandin synthesis in congestive heart failure and interactions with captopril. Br Heart J 1995; 73: 434-41
8. Teo KK, Yusuf S, Pfeffer M, et al. Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review [published erratum appears in Lancet 2003; 361 (9351): 90]. Lancet 2002; 360 (9339): 1037-43
9. Meune C, Mahe I, Mourad JJ, et al. Interaction between angiotensin-converting enzyme inhibitors and aspirin: a review. Eur J Clin Pharmacol 2000; 56 (9-10): 609-20
10. Stys T, Lawson WE, Smaldone GC, et al. Does aspirin attenuate the beneficial effects of angiotensin-converting enzyme inhibition in heart failure? Arch Intern Med 2000; 160 (10): 1409-13
11. Teerlink JR, Massie BM. The interaction of ACE inhibitors and aspirin in heart failure: torn between two lovers. Am Heart J 1999; 138 (2 Pt 1): 193-7
12. Carosella L, Pahor M, Pedone C, et al. Pharmacosurveillance in hospitalized patients in Italy: study design of the 'Gruppo Italiano di Farmacovigilanza nell'Anziano' (GIFA). Pharmacol Res 1999; 40 (3): 287-95
13. Hodkinson HM. Evaluation of a mental test score for assessment of mental impairment in the elderly. Age Ageing 1972; 1 (4): 233-8
14. Rocca WA, Bonaiuto S, Lippi A, et al. Validation of the Hodkinson abbreviated mental test as a screening instrument for dementia in an Italian population. Neuroepidemiology 1992; 11 (4-6): 288-95
15. Katz S, Ford AB, Moskowitz RW, et al. Studies of illness in the aged: the index of ADL - a standardized measure of biological and psychosocial function. JAMA 1963; 185: 914-9
16. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969; 9 (3): 179-86
17. Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc 1968; 16 (5): 622-6
18. Conwell Y, Forbes NT, Cox C, et al. Validation of a measure of physical illness burden at autopsy: the Cumulative Illness Rating Scale. J Am Geriatr Soc 1993; 41 (1): 38-41
19. Hosmer DW, Lemeshow S. Parametric regression models: applied survival analysis. 1st ed. New York: John Wiley & Sons, 1999: 271-306
20. Rothman KJ, Greenland S. Modern epidemiology. 2nd ed. Philadelphia (PA): Lippincott Williams & Wilkins, 1998
21. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Bethesda (MD): National Heart, Lung, and Blood Institute, 1998
22. Rothman KJ. Epidemiology: an introduction. 1st ed. New York: Oxford University Press, 2002
23. Hosmer DW, Lemeshow S. Confidence interval estimation of interaction. Epidemiology 1992; 3 (5): 452-6
24. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995; 273 (18): 1450-6
25. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Circulation 2001; 104 (24): 2996-3007
26. Bungard TJ, McAlister FA, Johnson JA, et al. Underutilisation of ACE inhibitors in patients with congestive heart failure. Drugs 2001; 61 (14): 2021-33
27. Nohria A, Chen YT, Morton DJ, et al. Quality of care for patients hospitalized with heart failure at academic medical centers. Am Heart J 1999; 137 (6): 1028-34
28. Materson BJ. Adverse effects of angiotensin-converting enzyme inhibitors in antihypertensive therapy with focus on quinapril. Am J Cardiol 1992; 69 (10): 46C-53C
29. Pedone C, Pahor M, Carosella L, et al. Use of angiotensin-converting enzyme-inhibitors in elderly people with heart failure: prevalence and outcomes. J Gerontol A Biol Sci Med Sci 2004; 59 (7): 716-21
30. Gambassi G, Lapane KL, Sgadari A, et al. Effects of angiotensin- converting enzyme inhibitors and digoxin on health outcomes of very old patients with heart failure. SAGE Study Group: systematic assessment of geriatric drug use via epidemiology. Arch Intern Med 2000; 160 (1): 53-60
31. Havranek EP, Abrams F, Stevens E, et al. Determinants of mortality in elderly patients with heart failure: the role of angiotensin-converting enzyme inhibitors. Arch Intern Med 1998; 158 (18): 2024-8
32. Jessup M, Brozena S. Heart failure. N Engl J Med 2003; 348 (20): 2007-18
33. Collaborative overview of randomised trials of antiplatelet therapy. I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308 (6921): 81-106
34. Krumholz HM, Chen YT, Radford MJ. Aspirin and the treatment of heart failure in the elderly. Arch Intern Med 2001; 161 (4): 577-82
35. Guazzi M, Brambilla R, Reina G, et al. Aspirin-angiotensin-converting enzyme inhibitor coadministration and mortality in patients with heart failure: a dose-related adverse effect of aspirin. Arch Intern Med 2003; 163 (13): 1574-9
36. Peterson JG, Topol EJ, Sapp SK, et al. Evaluation of the effects of aspirin combined with angiotensin-converting enzyme inhibitors in patients with coronary artery disease. Am J Med 2000; 109 (5): 371-7
37. Takkouche B, Etminan M, Caamano F, et al. Interaction between aspirin and ACE inhibitors: resolving discrepancies using a meta-analysis. Drug Saf 2002; 25 (5): 373-8
38. Lapane KL, Hume AL, Barbour MM, et al. Does aspirin attenuate the effect of angiotensin-converting enzyme inhibitors on health outcomes of very old patients with heart failure? J Am Geriatr Soc 2002; 50 (7): 1198-204
39. Leor J, Reicher-Reiss H, Goldbourt U, et al. Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors: a cohort study of 11,575 patients with coronary artery disease. J Am Coll Cardiol 1999; 33 (7): 1920-5
40. Krumholz HM, Chen YT, Wang Y, et al. Aspirin and angiotensin-converting enzyme inhibitors among elderly survivors of hospitalization for an acute myocardial infarction. Arch Intern Med 2001; 161 (4): 538-44
41. Harjai KJ, Solis S, Prasad A, et al. Use of aspirin in conjunction with angiotensin-converting enzyme inhibitors does not worsen long-term survival in heart failure. Int J Cardiol 2003; 88 (2-3): 207-14
42. Ahmed A. Interaction between aspirin and angiotensin-converting enzyme inhibitors: should they be used together in older adults with heart failure? J Am Geriatr Soc 2002; 50 (7): 1293-6
43. Aumegeat V, Lamblin N, de Groote P, et al. Aspirin does not adversely affect survival in patients with stable congestive heart failure treated with angiotensin-converting enzyme inhibitors. Chest 2003; 124 (4): 1250-8
44. Etminan M. Quantifying the interaction between angiotensin-converting enzyme inhibitors and aspirin: are we using the right method? Pharmacotherapy 2001; 21 (10): 1247-9
45. Wilson JR, Reichek N, Dunkman WB, et al. Effect of diuresis on the performance of the failing left ventricle in man. Am J Med 1981; 70 (2): 234-9
46. Parker JO. The effects of oral ibopamine in patients with mild heart failure: a double blind placebo controlled comparison to furosemide. The Ibopamine Study Group. Int J Cardiol 1993; 40 (3): 221-7
47. The effect of digoxin on mortality and morbidity in patients with heart failure: the Digitalis Investigation Group. N Engl J Med 1997; 336 (8): 525-33
48. Lee DS, Mamdani MM, Austin PC, et al. Trends in heart failure outcomes and pharmacotherapy: 1992 to 2000. Am J Med 2004; 116 (9): 581-9
49. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group. Lancet 1997; 349 (9049): 375-80
50. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina: summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 2003; 41 (1): 159-68
51. Kristianson K, Fyhrquist F, Devereux RB, et al. An analysis of cholesterol control and statin use in the Losartan Intervention for Endpoint Reduction in Hypertension Study. Clin Ther 2003; 25 (4): 1186-99
52. Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 355 (9215): 1575-81
53. Pocock SJ, Elbourne DR. Randomized trials or observational tribulations? N Engl J Med 2000; 342 (25): 1907-9
54. Frohlich ED. Treating hypertension: what are we to believe? N Engl J Med 2003; 348 (7): 639-41